Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Monte Rosa Therapeutics stock

Learn how to easily invest in Monte Rosa Therapeutics stock.

Monte Rosa Therapeutics is a biotechnology business based in the US. Monte Rosa Therapeutics shares (GLUE) are listed on the NASDAQ and all prices are listed in US Dollars. Monte Rosa Therapeutics employs 118 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy Monte Rosa Therapeutics stock

  1. Open a stock trading account. Use our comparison table or choose from our Top Picks.
  2. Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
  3. Search for the stock by name or ticker symbol – GLUE. It's that simple.

Best for low fees

Finder Award

SoFi Invest


  • Trade stocks for $0 and no annual fee
  • Start trading with a $0 minimum deposit
  • Get up to $1,000 when you fund a new account within 30 days

Best for beginners

Finder Award

eToro


  • Trade stocks and ETFs for $0 and no annual fee
  • Minimum deposit of $10 required
  • FINDER EXCLUSIVE: Get $15 when you sign up and deposit $100

Promoted for easy user experience

Robinhood


  • Get free stock upon signup
  • Earn 4% interest on uninvested cash with Robinhood Gold
  • Get 1% match on contributions to a Robinhood IRA

Monte Rosa Therapeutics stock price (NASDAQ: GLUE)

Use our graph to track the performance of GLUE stocks over time.

Monte Rosa Therapeutics shares at a glance

Information last updated 2023-02-01.
Latest market close$7.23
52-week range$6.05 - $15.54
50-day moving average $8.09
200-day moving average $8.80
Wall St. target price$21.89
PE ratio 1.4204
Dividend yield $0 (0%)
Earnings per share (TTM) $5.09

Buy Monte Rosa Therapeutics stocks from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Available asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get up to $1,000
when you fund a new account within 30 days.
Winner of Finder’s Best Low-Cost Broker award.
Finder Award
eToro
Stocks, Options, ETFs, Cryptocurrency
$0
$10
FINDER EXCLUSIVE: Get $15
when you sign up and deposit $100
Winner of Finder’s Best Broker for Beginners award. Not available in NY, NV, MN, TN, and HI.
Robinhood
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 4% interest on uninvested cash in your account with Robinhood Gold.
tastyworks
Stocks, Options, ETFs, Cryptocurrency
$0
$0
Get $200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Highly commended for Best Derivatives Trading Platform award.
Public.com
Stocks, ETFs, Cryptocurrency, Alternatives
$0
$0
Get up to $300 in either stocks or crypto
when you use code FINDERUS to sign up and fund a new account.
Trade stocks and ETFs commission-free, plus gain access to alternative investments like art, NFTs and more.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency, Futures, Forex
$0
$0
N/A
Winner of Finder’s Best Overall Stock Broker award.
loading

Compare up to 4 providers

Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.

Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.

Is it a good time to buy Monte Rosa Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monte Rosa Therapeutics price performance over time

Historical closes compared with the close of $7.23 from 2023-02-01

1 week (2023-01-26) 5.86%
1 month (2023-01-03) -7.07%
3 months (2022-11-03) -12.47%
6 months (2022-08-03) -19.31%
1 year (2022-02-03) -42.30%
2 years (2021-01-30) N/A
3 years (2020-01-30) N/A
5 years (2018-01-30) N/A

Is Monte Rosa Therapeutics stock undervalued or overvalued?

Valuing Monte Rosa Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Monte Rosa Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Monte Rosa Therapeutics's P/E ratio

Monte Rosa Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 1x. In other words, Monte Rosa Therapeutics shares trade at around 1x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.

However, Monte Rosa Therapeutics's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.

    Monte Rosa Therapeutics financials

    Gross profit TTM $0
    Return on assets TTM -17.41%
    Return on equity TTM -30.64%
    Profit margin 0%
    Book value $6.02
    Market capitalisation $349.9 million

    TTM: trailing 12 months

    Monte Rosa Therapeutics share dividends

    We're not expecting Monte Rosa Therapeutics to pay a dividend over the next 12 months.

    Monte Rosa Therapeutics overview

    Monte Rosa Therapeutics, Inc. , a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts. .

    Frequently asked questions

    What percentage of Monte Rosa Therapeutics is owned by insiders or institutions?
    Currently 0.861% of Monte Rosa Therapeutics shares are held by insiders and 97.827% by institutions.
    How many people work for Monte Rosa Therapeutics?
    Latest data suggests 118 work at Monte Rosa Therapeutics.
    When does the fiscal year end for Monte Rosa Therapeutics?
    Monte Rosa Therapeutics's fiscal year ends in December.
    Where is Monte Rosa Therapeutics based?
    Monte Rosa Therapeutics's address is: 645 Summer Street, Boston, MA, United States, 02210
    What is Monte Rosa Therapeutics's ISIN number?
    Monte Rosa Therapeutics's international securities identification number is: US61225M1027

    More guides on Finder

    Ask an Expert

    Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

    By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

    Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
    Go to site